What is the recommended linezolid dose and duration for treating community‑acquired or hospital‑acquired bacterial pneumonia in adults and children?

Linezolid Dosing for Pneumonia

For adults with community-acquired or hospital-acquired pneumonia, linezolid should be dosed at 600 mg IV or oral every 12 hours for 7-21 days depending on severity and pathogen, while children <12 years require 10 mg/kg every 8 hours and children ≥12 years receive 600 mg every 12 hours.

Adult Dosing

Standard Regimen

• Dose: 600 mg IV or oral every 12 hours 1
• Duration:
  • Community-acquired pneumonia: 7-14 days 1
  • Hospital-acquired/nosocomial pneumonia: 7-21 days 1, 2
  • MRSA pneumonia with bacteremia: up to 28 days 1

Clinical Context for Use

MRSA Pneumonia (primary indication):

• Linezolid is recommended as first-line therapy alongside vancomycin for MRSA pneumonia 3
• For hospital-acquired MRSA pneumonia, linezolid 600 mg IV/PO twice daily is an A-II recommendation 4, 3
• Clinical trial data shows linezolid achieved 57.6% clinical success vs 46.6% for vancomycin in MRSA nosocomial pneumonia (P=0.042) 5

Community-Acquired Pneumonia:

• Linezolid is reserved for specific situations in CAP 6:
  • Patients with risk factors for MRSA (prior MRSA infection, recent hospitalization with IV antibiotics in past 90 days)
  • Severe CAP requiring ICU admission with suspected MRSA
  • Should be combined with cultures/nasal PCR to allow de-escalation 6

Hospital-Acquired Pneumonia:

• For patients at high risk of mortality or with recent IV antibiotic use, add MRSA coverage with vancomycin or linezolid 7
• Linezolid is preferred over vancomycin when nephrotoxicity is a concern (nephrotoxicity: 8.4% vs 18.2%) 5

Pediatric Dosing

Age-Based Regimens 8, 1

Children <12 years:

• Dose: 10 mg/kg IV or oral every 8 hours (30 mg/kg/day total)
• Maximum single dose: 600 mg

Children ≥12 years and adolescents:

• Dose: 600 mg IV or oral every 12 hours (adult dosing)

Neonates (special considerations) 1:

• Preterm <7 days old (<34 weeks gestational age): 10 mg/kg every 12 hours initially
• Consider increasing to 10 mg/kg every 8 hours if suboptimal response
• Full-term neonates: 10 mg/kg every 8 hours by 7 days of life

Pediatric Indications 8

MRSA pneumonia:

• Preferred: Vancomycin 15 mg/kg/dose IV every 6 hours
• Alternative: Linezolid 10 mg/kg every 8 hours (<12 years) or 600 mg every 12 hours (≥12 years) 8, 4
• If patient is stable without bacteremia, clindamycin may be used if susceptible

Resistant pneumococcal pneumonia (MIC ≥4.0 μg/mL):

• Parenteral: Linezolid 10 mg/kg every 8 hours (<12 years) as alternative 8
• Oral step-down: Linezolid 10 mg/kg every 8 hours (<12 years) or 600 mg every 12 hours (≥12 years) 8

Critical Dosing Considerations

Route of Administration

• Bioavailability is 100% - IV and oral dosing are equivalent 1
• Switch from IV to oral when clinically appropriate without dose adjustment 1
• Can be given without regard to meals 1

Duration Optimization

• Minimum effective duration: 7 days for most pneumonia 1
• CAP/HAP without complications: 7-14 days typically sufficient 2, 9
• Severe MRSA pneumonia: 14-21 days 3
• With bacteremia: May extend to 28 days 1
• Recent guidelines suggest shorter courses (3-5 days) may be adequate for non-severe CAP reaching clinical stability, though this applies primarily to beta-lactam therapy 10

Safety Monitoring

• Thrombocytopenia risk increases with duration >14 days
• Trough levels: Target Cmin,ss <8 mg/L to minimize toxicity 11
• Monitor CBC weekly, especially with prolonged therapy
• Nephrotoxicity significantly lower than vancomycin (8.4% vs 18.2%) 5

Common Pitfalls

1. Underdosing children: Remember pediatric patients <12 years require every-8-hour dosing (not every 12 hours) due to faster clearance 1

2. Inappropriate empiric use: Linezolid should not be routine first-line for CAP unless specific MRSA risk factors present 6. Always obtain cultures to allow de-escalation.

3. Prolonged therapy without monitoring: Extended courses beyond 14 days significantly increase hematologic toxicity risk - reassess need for continuation 11

4. Ignoring renal function: While linezolid dose doesn't require adjustment for renal insufficiency, metabolites accumulate and clinical significance is unknown 1. Use cautiously in severe renal impairment.

5. Continuous infusion misconceptions: Recent data suggests continuous infusion may increase toxicity without efficacy gains for high-MIC pathogens; intermittent dosing with 2-5 hour infusions may optimize the therapeutic index 11